What's breaking now, across thousands of outlets.
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients' tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.
We haven't written up this one. CBC News has the full story — the link below goes straight to it.
RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH) is advancing gene therapy for sickle cell disease through a 2026 clinical trial that…
Another day, another Roche deal. The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell engager (TCE) that could go head-to-head with…
Researchers analyzed mulitomic and clinical data from 2000 colorectal cancer samples and used an AI tool, iPhenMap, to help identify cancer cell vulnerabilities and drug combinations that could be…
People with severe mental illness experienced more rapid increases in both weight and long-term blood sugar levels during the first three months after starting treatment with antipsychotic medication…
(MedPage Today) -- Adjuvant treatment with the mRNA-based cancer vaccine intismeran autogene plus pembrolizumab (Keytruda) significantly improved recurrence-free survival (RFS) in patients with…
